FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs
Sharp increases in deaths from illicit drugs (heroin and synthetic opioids) could change FDA's priorities; rather than working with drug sponsors on more tamper-deterrent formulations of pain therapies, the agency may need to devote more attention to overdose treatments like naloxone.
You may also be interested in...
FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.
Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.